Currently, seasonal flu vaccines are designed to induce high levels of protective antibodies
against hemagglutinin (HA), a protein found on the surface of the influenza virus that enables the virus to enter a human cell and initiate infection.
Most traditional vaccines generate antibodies
against the hemagglutinin head.
The immune system commonly makes antibodies
against hemagglutinin that foil the strain's ability to infect the host again.
Not exact matches
We found that the mutations in two amino acids out of more than 300 in one key region of the
hemagglutinin protein were enough to lower efficacy to 19 percent
against all circulating strains.»
Like kids with a sweet tooth, the immune system gets most excited about the top part of the
hemagglutinin lollipop, and makes antibodies
against it.
People with higher levels of antibodies
against the stem portion of the influenza virus
hemagglutinin (HA) protein have less viral shedding when they get the flu, but do not have fewer or less severe signs of illness, according to a new study published in mBio.
Unlike antibodies elicited by annual influenza vaccinations, most neutralizing antibodies induced by pandemic H1N1 infection were broadly cross-reactive
against epitopes in the
hemagglutinin (HA) stalk and head domain of multiple influenza strains.